이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Elevance Health 관리
관리 기준 확인 3/4
Elevance Health's CEO는 Gail Boudreaux, Nov2017 에 임명되었습니다 의 임기는 6.58 년입니다. 총 연간 보상은 $ 21.89M, 7.3% 로 구성됩니다. 7.3% 급여 및 92.7% 보너스(회사 주식 및 옵션 포함). 는 $ 75.94M 가치에 해당하는 회사 주식의 0.062% 직접 소유합니다. 75.94M. 경영진과 이사회의 평균 재임 기간은 각각 6.2 년과 10.8 년입니다.
주요 정보
Gail Boudreaux
최고 경영자
US$21.9m
총 보상
| CEO 급여 비율 | 7.3% |
| CEO 임기 | 6.6yrs |
| CEO 소유권 | 0.06% |
| 경영진 평균 재임 기간 | 6.2yrs |
| 이사회 평균 재임 기간 | 10.8yrs |
최근 관리 업데이트
Recent updates
Elevance Health: Favorable Trends Are Emerging (Rating Upgrade)
Jun 28Is Now An Opportune Moment To Examine Elevance Health, Inc. (NYSE:ELV)?
Jun 11
Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher
May 27We Think Shareholders Will Probably Be Generous With Elevance Health, Inc.'s (NYSE:ELV) CEO Compensation
May 09Elevance Health (NYSE:ELV) Has Announced A Dividend Of $1.63
Apr 25Elevance Health: It's Not Too Late To Buy Their Dividend Growth
Apr 23Is Elevance Health (NYSE:ELV) Using Too Much Debt?
Apr 16Elevance Health: Not Doing Enough In 2024 To Justify Premium Price
Apr 11Elevance Health, Inc.'s (NYSE:ELV) Earnings Haven't Escaped The Attention Of Investors
Apr 01Elevance: A Healthy Dose Of Dividend Growth
Mar 21Elevance Heath: Financial Growth And Technical Strength Indicate A Buy
Mar 07Elevance Health (NYSE:ELV) Will Pay A Larger Dividend Than Last Year At $1.63
Feb 19Elevance Health: Time To Buy This Incredible Dividend Growth Stock
Jan 26Slowing Rates Of Return At Elevance Health (NYSE:ELV) Leave Little Room For Excitement
Jan 19Is Elevance Health (NYSE:ELV) A Risky Investment?
Jan 02Elevance Health, Inc.'s (NYSE:ELV) Shares Not Telling The Full Story
Dec 18A Look At Elevance's Margin Dynamics
Nov 23Is It Time To Consider Buying Elevance Health, Inc. (NYSE:ELV)?
Nov 16Elevance Health: A High Conviction Defensive Blue Chip Buy
Oct 19These 4 Measures Indicate That Elevance Health (NYSE:ELV) Is Using Debt Safely
Oct 04Elevance: Pave The Way For The Next UnitedHealth
Sep 21Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Sep 18Here's The Price I Would Buy Elevance Health Stock
Sep 13If EPS Growth Is Important To You, Elevance Health (NYSE:ELV) Presents An Opportunity
Aug 18Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
Aug 04Narrowing Down High-Quality Dividend Growth: Elevance Health Is Elemental
Jul 24Elevance Health: Beaten Down Share Price Offers Solid Potential
Jul 10Here's Why Elevance Health (NYSE:ELV) Can Manage Its Debt Responsibly
Jul 05Elevance Health: A Critical Update (Rating Downgrade)
Jun 05Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher
Jun 04Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
May 05We Think Elevance Health (NYSE:ELV) Can Stay On Top Of Its Debt
Apr 04Elevance Health's (NYSE:ELV) Dividend Will Be Increased To $1.48
Feb 17Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Feb 13Elevance Health: Attractive On Its Expansion Catalysts
Feb 09Elevance Health (NYSE:ELV) Has Announced That It Will Be Increasing Its Dividend To $1.48
Jan 28Elevance Health acquiring Blue Cross and Blue Shield of Louisiana
Jan 23Elevance Health Offers Great Value
Jan 17At US$483, Is Elevance Health Inc. (NYSE:ELV) Worth Looking At Closely?
Jan 17Elevance Health: Strong And Steady EPS Growth Ahead, High Relative Strength Name
Jan 02Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly
Nov 28Does Elevance Health (NYSE:ELV) Deserve A Spot On Your Watchlist?
Nov 16Elevance Health to acquire speciality pharmacy from CarepathRx
Nov 09Elevance Health (NYSE:ELV) Is Doing The Right Things To Multiply Its Share Price
Nov 02Elevance Health declares $1.28 dividend
Oct 19Are Investors Undervaluing Elevance Health Inc. (NYSE:ELV) By 37%?
Oct 12Elevance affiliates to offer affordable Medicare Advantage plans
Oct 10CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$22m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$6b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$21m | US$2m | US$6b |
| Sep 30 2022 | n/a | n/a | US$6b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$19m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$17m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$5b |
| Jun 30 2020 | n/a | n/a | US$6b |
| Mar 31 2020 | n/a | n/a | US$5b |
| Dec 31 2019 | US$15m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$4b |
| Jun 30 2019 | n/a | n/a | US$4b |
| Mar 31 2019 | n/a | n/a | US$4b |
| Dec 31 2018 | US$14m | US$1m | US$4b |
| Sep 30 2018 | n/a | n/a | US$5b |
| Jun 30 2018 | n/a | n/a | US$4b |
| Mar 31 2018 | n/a | n/a | US$4b |
| Dec 31 2017 | US$3m | US$162k | US$4b |
보상 대 시장: Gail 의 총 보상 ($USD 21.89M )은 US 시장( $USD 13.50M ).
보상과 수익: Gail 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Gail Boudreaux (63 yo)
6.6yrs
테뉴어
US$21,889,039
보상
Ms. Gail Koziara Boudreaux has been an Independent Director at Target Corporation since September 23, 2021. She has been President, Chief Executive Officer and Director of Elevance Health Inc. (formerly kn...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 6.6yrs | US$21.89m | 0.062% $ 78.0m | |
| Executive VP & CFO | less than a year | US$12.36m | 데이터 없음 | |
| EVP, Chief Legal & Administrative Officer | 3.6yrs | US$8.11m | 0.0044% $ 5.6m | |
| Executive VP and President of Carelon & CarelonRx | 10yrs | US$6.98m | 0.0063% $ 7.9m | |
| Executive VP & President of Government Health Benefits | 6yrs | US$6.48m | 0.0097% $ 12.3m | |
| SVP, Treasurer & Chief Investment Officer | 6.2yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP | 8.6yrs | 데이터 없음 | 0.00057% $ 717.8k | |
| Chief Information Officer | no data | 데이터 없음 | 데이터 없음 | |
| Vice President of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Public Affairs | 10.6yrs | 데이터 없음 | 데이터 없음 | |
| Chief Strategy Officer & Interim Chief Marketing Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Executive VP and President of Commercial & Specialty Health Benefits | no data | 데이터 없음 | 0.0050% $ 6.2m |
6.2yrs
평균 재임 기간
58yo
평균 연령
경험이 풍부한 관리: ELV 의 관리팀은 노련하고 경험 (평균 재직 기간 6.2 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 6.6yrs | US$21.89m | 0.062% $ 78.0m | |
| Independent Director | 19.6yrs | US$386.76k | 0.0027% $ 3.4m | |
| Independent Chair of the Board | 10.7yrs | US$597.83k | 0% $ 0 | |
| Independent Director | 10.9yrs | US$362.53k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$371.42k | 0% $ 0 | |
| Independent Director | 10.1yrs | US$371.42k | 0% $ 0 | |
| Independent Director | 4.7yrs | US$347.28k | 0.0013% $ 1.6m | |
| Independent Director | 12.9yrs | US$360.34k | 0.0029% $ 3.7m | |
| Member of Advisory Board | 10.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Advisory Board | 10.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Advisory Board | 10.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Advisory Board | 10.8yrs | 데이터 없음 | 데이터 없음 |
10.8yrs
평균 재임 기간
68yo
평균 연령
경험이 풍부한 이사회: ELV 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.8 년).